[pending] PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
Pending LLM rewrite. Source: FDA_DRUG D-0349-2025.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
CGMP Deviations
The recalled product
- Product
- PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
- Brand
- PRAVASTATIN SODIUM
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 17230810
- exp. date Mar-26
UPCs (3)
- 0316714570013
- 0316714559018
- 0316714560014
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · PRAVASTATIN SODIUM
- ModeratePravastatin Sodium Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2025-04-16
- HighPravastatin Sodium Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2024-07-24
- HighFDA Recalls Pravastatin Sodium Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- HighPravastatin Sodium tablets recalled for manufacturing practice violations
FDA (Drugs) · 2023-03-08
- ModeratePravastatin Sodium Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27